Verona Pharma PLC (VRNA)
37.86
-0.99
(-2.55%)
USD |
NASDAQ |
Nov 21, 16:00
37.93
+0.07
(+0.18%)
After-Hours: 20:00
Verona Pharma Net Income (Quarterly): -42.96M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -42.96M |
June 30, 2024 | -70.84M |
March 31, 2024 | -25.79M |
December 31, 2023 | -14.13M |
September 30, 2023 | -14.69M |
June 30, 2023 | -8.807M |
March 31, 2023 | -16.74M |
December 31, 2022 | -10.45M |
September 30, 2022 | -15.65M |
June 30, 2022 | -17.77M |
March 31, 2022 | -24.84M |
December 31, 2021 | -23.26M |
September 30, 2021 | 11.05M |
June 30, 2021 | -22.07M |
March 31, 2021 | -21.29M |
December 31, 2020 | -24.82M |
September 30, 2020 | -18.93M |
Date | Value |
---|---|
June 30, 2020 | -9.038M |
March 31, 2020 | -12.35M |
December 31, 2019 | -9.543M |
September 30, 2019 | -12.48M |
June 30, 2019 | -11.37M |
March 31, 2019 | -7.051M |
December 31, 2018 | -3.166M |
September 30, 2018 | -3.049M |
June 30, 2018 | 0.7988M |
March 31, 2018 | -21.34M |
December 31, 2017 | -8.639M |
September 30, 2017 | -12.21M |
June 30, 2017 | -4.163M |
March 31, 2017 | -2.388M |
December 31, 2016 | -0.672M |
September 30, 2016 | -3.207M |
June 30, 2016 | -1.091M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-70.84M
Minimum
Jun 2024
11.05M
Maximum
Sep 2021
-19.65M
Average
-17.25M
Median
Net Income (Quarterly) Benchmarks
Biodexa Pharmaceuticals PLC | -- |
TC BioPharm (Holdings) PLC | -4.213M |
Adaptimmune Therapeutics PLC | -17.62M |
NuCana PLC | -8.826M |
Autolus Therapeutics PLC | -82.09M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 5.624M |
Total Expenses (Quarterly) | 44.68M |
EPS Diluted (Quarterly) | -0.56 |
Enterprise Value | 2.882B |
Gross Profit Margin (Quarterly) | 90.34% |
Profit Margin (Quarterly) | -763.9% |
Earnings Yield | -5.28% |
Normalized Earnings Yield | -5.264 |